Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparison of epcoritamab, lenalidomide, and rituximab versus usual care in relapsed/refractory follicular lymphoma.

Oncoimmunology·2026

Same author

Pharmacologic activity, safety, and preliminary efficacy of GEN3009, a CD37-targeting DuoHexaBody, in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Journal for immunotherapy of cancer·2026

Same author

Blood-brain barrier permeability in diffuse large B-Cell lymphoma: associations with established risk factors for CNS relapse.

Tissue barriers·2026

Same author

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

HemaSphere·2026

Same author

Assessing subcortical, brainstem and cerebellar metabolic patterns using [18F]FDG PET-CT imaging in dementia with Lewy bodies.

European journal of nuclear medicine and molecular imaging·2026

Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)·2026

Search research articles

Related Experiment Video

Updated: May 18, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

FDG-PET/CT based response-adapted treatment.

Lioe-Fee de Geus-Oei¹, Dennis Vriens, Anne I J Arens

¹Department of Nuclear Medicine, Radboud University Nijmegen Medical Centre, The Netherlands. l.degeus-oei@nucmed.umcn.nl

Cancer Imaging : the Official Publication of the International Cancer Imaging Society

|October 2, 2012

Summary

This summary is machine-generated.

[(18)F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) enables early metabolic response assessment in cancers. PET-guided treatment individualization in lymphoma and esophagogastric cancer trials aims to improve survival and reduce toxicity.

More Related Videos

Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT

Functional Imaging of Brown Fat in Mice with ¹⁸F-FDG micro-PET/CT

Published on: November 23, 2012

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing ¹⁸F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Experiment Videos

Last Updated: May 18, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Functional Imaging of Brown Fat in Mice with 18F-FDG micro-PET/CT

Functional Imaging of Brown Fat in Mice with ¹⁸F-FDG micro-PET/CT

Published on: November 23, 2012

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Utilizing ¹⁸F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Area of Science:

Oncology
Nuclear Medicine
Medical Imaging

Background:

[(18)F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) is a validated tool for assessing early metabolic response in malignancies.
Prospective multicenter trials are investigating PET-guided treatment individualization in malignant lymphoma and esophagogastric junction adenocarcinoma.
Current research focuses on optimizing treatment strategies based on individual patient metabolic response.

Purpose of the Study:

To evaluate the survival benefit of PET-guided treatment individualization in lymphoma and esophagogastric junction adenocarcinoma.
To explore the use of PET for early identification of metabolic responders and non-responders to guide treatment intensification or de-escalation.
To establish response-guided treatment algorithms for various malignancies.

Main Methods:

Prospective multicenter trials in Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, and adenocarcinoma of the esophagogastric junction.
Utilizing FDG-PET for early metabolic response assessment during neoadjuvant chemotherapy.
Comparing outcomes for patients receiving PET-guided adaptive therapy versus standard treatment protocols.

Main Results:

In esophagogastric junction adenocarcinoma, patients with early metabolic response to neoadjuvant chemotherapy showed improved outcomes.
Metabolic non-responders in these trials benefited from early switch to surgery, reducing risks of progression and toxic death.
Ongoing trials in lymphoma aim to correlate metabolic response with survival and treatment toxicity.

Conclusions:

PET-guided treatment algorithms offer a promising future for personalized cancer therapy, adjusting treatment intensity and duration based on individual patient biology.
Early metabolic response assessment via FDG-PET can guide treatment decisions to improve outcomes and minimize toxicity.
Further research is crucial to confirm the impact of personalized, response-adapted treatment concepts on overall patient survival.